公开(公告)号：US07067554B2

公开(公告)日：2006-06-27

申请号：US10611741

申请日：2003-07-01

申请人： Adnan M. M. Mjalli ,  Ramesh Gopalaswamy ,  Kwasi A. Avor ,  Christopher L. Wysong ,  Patron Andrew

发明人： Adnan M. M. Mjalli ,  Ramesh Gopalaswamy ,  Kwasi A. Avor ,  Christopher L. Wysong ,  Patron Andrew

IPC分类号： A61K31/21 ,  C07C233/00

CPC分类号： C07C311/19 ,  A61K31/16 ,  C07C237/20 ,  C07C237/22 ,  C07C271/22 ,  C07C275/24 ,  C07C279/14 ,  C07C311/06 ,  C07D307/42 ,  Y10S977/915

摘要： This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, β-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.

公开(公告)号：US06613801B2

公开(公告)日：2003-09-02

申请号：US09799317

申请日：2001-03-05

申请人： Adnan M. M. Mjalli ,  Ramesh Gopalaswamy ,  Kwasi S. Avor ,  Christopher L. Wysong ,  Andrew Patron

发明人： Adnan M. M. Mjalli ,  Ramesh Gopalaswamy ,  Kwasi S. Avor ,  Christopher L. Wysong ,  Andrew Patron

IPC分类号： A61K3127

CPC分类号： C07C311/19 ,  A61K31/16 ,  C07C237/20 ,  C07C237/22 ,  C07C271/22 ,  C07C275/24 ,  C07C279/14 ,  C07C311/06 ,  C07D307/42 ,  Y10S977/915

摘要： This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, &bgr;-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.

公开(公告)号：US07776919B2

公开(公告)日：2010-08-17

申请号：US12019045

申请日：2008-01-24

申请人： Adnan M. M. Mjalli ,  Robert C. Andrews ,  Ramesh Gopalaswamy ,  Christopher L. Wysong

发明人： Adnan M. M. Mjalli ,  Robert C. Andrews ,  Ramesh Gopalaswamy ,  Christopher L. Wysong

IPC分类号： A01N37/18 ,  C07C237/00 ,  C07C233/00 ,  C07C235/00

CPC分类号： C07D231/12 ,  C07C235/38 ,  C07C237/20 ,  C07C271/22 ,  C07C2601/08 ,  C07C2603/18 ,  C07D207/16 ,  C07D211/34 ,  C07D217/26 ,  C07D233/56 ,  C07D249/08 ,  C07D309/04

摘要： This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, β-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.

摘要翻译： 本发明提供某些化合物，其制备方法，包含该化合物的药物组合物及其在治疗人或动物疾病中的用途。 本发明的化合物可用作晚期糖基化终产物（RAGE）的受体与其配体如晚期糖基化终产物（AGE），S100 /钙粒蛋白/ EN-RAGE，淀粉样蛋白和 两性霉素，以及由RAGE引起的人类疾病的管理，治疗，控制或辅助治疗。 这些疾病或疾病状态包括急性和慢性炎症，糖尿病晚期并发症的发展，例如血管通透性增加，肾病，动脉粥样硬化和视网膜病变，阿尔茨海默病的发展，勃起功能障碍和肿瘤侵袭和转移。